External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort
Dermatology · 2023
DOI: 10.1159/000528968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology, 2023. Verfasst von Kelsey R van Straalen und 33 weiteren Autor:innen. Beteiligte Einrichtung: European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 16-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It was validated in datasets of adalimumab and placebo-treated HS patients. External validation is an important aspect of clinical outcomes.
Objectives
We aimed to externally validate the novel dichotomous IHS4-55 in a non-biologic treated dataset of HS patients.
Methods
Data from a previously published European-wide prospective clinical study of antibiotic treatment of HS patients were used to assess the association of IHS4-55 achievement with individual reduction in inflammatory nodules, abscesses, and draining tunnels. Moreover, the associations between IHS4-55 positivity and achievement of the minimal clinically important differences (MCIDs) for Dermatology Life Quality Index (DLQI), Numerical Rating Scale (NRS) Pain, and NRS Pruritus were analyzed.
Results
Data were obtained from 283 individual patients, of which 36.4% (103/283) were treated with clindamycin and rifampicin and 63.6% (180/283) with tetracyclines for 12 weeks. Achievers of the IHS4-55 demonstrated a significant reduction the counts of inflammatory nodules, abscesses, and draining tunnels (all p < 0.001). Additionally, IHS4-55 achievers had an odds ratio for achieving the MCID of DLQI, NRS Pain, and NRS Pruritus of 2.16 (95% CI 1.28–3.65, p < 0.01), 1.79 (95% CI 1.10–2.91, p < 0.05), and 1.95 (95% CI 1.18–3.22, p < 0.01), respectively.
Conclusions
This study shows the external validity of the novel IHS4-55 by demonstrating a significant association between IHS4-55 achievement and a reduction in inflammatory lesion counts as well as achievement of MCIDs for DLQI, NRS Pain, and NRS Pruritus in an antibiotic-treated cohort. These findings support the use of the IHS4-55 as a novel primary outcome measure in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
- Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Dermatology, Nordland Hospital Trust, Bodø, Norway.
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Dermatology, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium.
- Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Zitieren
APA
van Straalen, K. R., Tzellos, T., Alavi, A., Benhadou, F., Cuenca-Barrales, C., Daxhelet, M., Daoud, M., Efthymiou, O., Giamarellos-Bourboulis, E. J., Guillem, P., Gulliver, W., Jemec, G. B. E., Katoulis, A., Koenig, A., Lazaridou, E., Lowes, M. A., Marzano, A. V., Matusiak, L., Molina-Leyva, A., …, & van der Zee, H. H. (2023). External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort. Dermatology. https://doi.org/10.1159/000528968
Vancouver
van Straalen KR, Tzellos T, Alavi A, Benhadou F, Cuenca-Barrales C, Daxhelet M, et al. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort. Dermatology. 2023. doi:10.1159/000528968
BibTeX
@article{vanStraalen2023,
author = {van Straalen, Kelsey R and Tzellos, Thrasyvoulos and Alavi, Afsaneh and Benhadou, Farida and Cuenca-Barrales, Carlos and Daxhelet, Mathilde and Daoud, Mathieu and Efthymiou, Ourania and Giamarellos-Bourboulis, Evangelos J and Guillem, Philippe and Gulliver, Wayne and Jemec, Gregor B E and Katoulis, Alexander and Koenig, Anke and Lazaridou, Elizabeth and Lowes, Michelle A and Marzano, Angelo V and Matusiak, Lukasz and Molina-Leyva, Alejandro and Moltrasio, Chiara and Pinter, Andreas and Potenza, Concetta and Prens, Errol P and Romaní, Jorge and Saunte, Ditte M and Sayed, Christopher and Skroza, Nevena and Stergianou, Dimitra and Szepietowski, Jacek C and Trigoni, Anastasia and Vilarrasa, Eva and Kyrgidis, Athanassios and Zouboulis, Christos C and van der Zee, Hessel H},
title = {External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort},
journal = {Dermatology},
year = {2023},
doi = {10.1159/000528968}
}
EUVIMED